Innoviva, Inc. (NASDAQ:INVA) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC lessened its stake in shares of Innoviva, Inc. (NASDAQ:INVA) by 17.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 28,200 shares of the biotechnology company’s stock after selling 5,784 shares during the quarter. Yousif Capital Management LLC’s holdings in Innoviva were worth $452,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of INVA. Quantbot Technologies LP purchased a new position in shares of Innoviva during the third quarter valued at approximately $29,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Innoviva by 342.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,410 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 5,736 shares during the last quarter. Avantax Advisory Services Inc. purchased a new stake in shares of Innoviva in the third quarter valued at $137,000. Profund Advisors LLC increased its stake in Innoviva by 7.9% in the third quarter. Profund Advisors LLC now owns 11,879 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 871 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its position in Innoviva by 11.1% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 12,000 shares of the biotechnology company’s stock worth $156,000 after buying an additional 1,200 shares during the period. Hedge funds and other institutional investors own 99.12% of the company’s stock.

Innoviva Price Performance

INVA stock opened at $15.45 on Tuesday. The company has a market cap of $976.86 million, a PE ratio of 7.09 and a beta of 0.57. The company has a current ratio of 9.03, a quick ratio of 7.96 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average price of $14.97 and a two-hundred day moving average price of $15.04. Innoviva, Inc. has a 12-month low of $11.55 and a 12-month high of $16.86.

Innoviva (NASDAQ:INVA) last posted its earnings results on Thursday, February 29th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter. The firm had revenue of $85.84 million during the quarter. Innoviva had a net margin of 57.89% and a return on equity of 30.37%.

Analysts Set New Price Targets

INVA has been the subject of a number of research analyst reports. TheStreet raised shares of Innoviva from a “c” rating to a “b-” rating in a research note on Thursday, February 29th. StockNews.com raised shares of Innoviva from a “hold” rating to a “buy” rating in a research note on Friday, March 29th.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.